Physician profile
Patrick Gresham
NPI 1700014511
$13,884.98
in general payments reported to CMS, 2019-2025
37 companies · $1,936 in 2025
The $1,936 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $1,640 · 2021: $2,193 · 2022: $2,368 · 2023: $2,321 · 2024: $2,113 · 2025: $1,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,324 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,323.94 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,531.61 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,214.69 | 2019-2025 | Trintellix |
| Lundbeck LLC | $1,196.40 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $1,172.23 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Tris Pharma INC | $1,106.20 | 2019-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $1,088.83 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $932.75 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $925.30 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $896.54 | 2019-2025 | Spravato |
| Neurocrine Biosciences, INC. | $601.61 | 2019-2025 | Ingrezza |
| Corium, LLC | $500.09 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $341.74 | 2019-2024 | Jornay Pm |
| Alkermes, INC. | $321.97 | 2021-2025 | Aristada, Lybalvi |
| Allergan, INC. | $206.12 | 2019-2020 | |
| Adlon Therapeutics L.P. | $194.85 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $159.42 | 2019 | |
| Sunovion Pharmaceuticals INC. | $155.47 | 2021-2022 | |
| Axsome Therapeutics, INC. | $139.62 | 2023-2024 | Auvelity |
| Arbor Pharmaceuticals, INC. | $136.12 | 2019-2021 | |
| Neos Therapeutics, LP | $134.42 | 2019-2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $130.20 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $121.34 | 2025 | Jornay Pm |
| Eisai INC. | $112.16 | 2020 | |
| Noven Therapeutics, LLC | $73.64 | 2024 | Xelstrym |
| Bausch Health US, LLC | $72.09 | 2021-2022 | |
| Harmony Biosciences LLC | $61.31 | 2024-2025 | |
| Indivior INC. | $49.38 | 2023 | Perseris |
| Sage Therapeutics, LLC | $45.33 | 2024-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $35.99 | 2022-2023 | Quviviq |
| Neuronetics, INC. | $34.78 | 2022 | |
| Owp Pharmaceuticals, INC. | $34.72 | 2022-2024 | Subvenite |
| Luye Pharma (USA) LTD. | $34.37 | 2025 | Erzofri Extended-Release |
| Avanir Pharmaceuticals, INC. | $31.86 | 2019 | |
| Livanova USA, INC. | $31.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $29.20 | 2019-2023 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $19.69 | 2022 | |
| Brainsway USA INC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gresham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.